Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fovepta
- Development stage
- Unknown
- Lead developer
- Biotest
- Administration
- Intramuscular, Subcutaneous, Intravenous
01
Overview
Fovepta (BT088) is a plasma-derived human hepatitis B immunoglobulin (HBIG) developed by Biotest Pharma GmbH, a subsidiary of Grifols. It contains a high concentration (500 IU/ml) of anti-HBs antibodies, providing immediate passive immunization against the hepatitis B virus (HBV). The product is primarily indicated for post-exposure prophylaxis, particularly in neonates born to HBV-carrier mothers, and for the prevention of hepatitis B reinfection in patients following liver transplantation due to HBV-induced liver failure. Fovepta is designed to achieve protective antibody titers rapidly and is typically administered via intramuscular or subcutaneous injection, often in conjunction with active hepatitis B vaccination.
- Brand names
- Fovepta
- Other names
- Human Hepatitis B ImmunoglobulinHBIGHuman Hepatitis-B Immunoglobulin
02
Targets
HBsAg (Hepatitis B surface antigen)
Beyond the preview
Go deeper on Fovepta.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Fovepta.